Hubbry Logo
POLGPOLGMain
Open search
POLG
Community hub
POLG
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
POLG
POLG
POLG
View on Wikipedia
from Wikipedia
POLG
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesPOLG, MDP1, MIRAS, MTDPS4A, MTDPS4B, PEO, POLG1, POLGA, SANDO, SCAE, polymerase (DNA) gamma, catalytic subunit, DNA polymerase gamma, catalytic subunit, ORF-Y, POLGARF
External IDsOMIM: 174763; MGI: 1196389; HomoloGene: 2016; GeneCards: POLG; OMA:POLG - orthologs
Orthologs
SpeciesHumanMouse
Entrez

5428

18975

Ensembl

ENSG00000140521

ENSMUSG00000039176

UniProt

P54098

P54099

RefSeq (mRNA)

NM_002693
NM_001126131

NM_017462
NM_001360095
NM_001360096

RefSeq (protein)

NP_001119603
NP_002684

n/a

Location (UCSC)Chr 15: 89.31 – 89.33 MbChr 7: 79.1 – 79.12 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

DNA polymerase subunit gamma (POLG or POLG1) is an enzyme that in humans is encoded by the POLG gene.[5] Mitochondrial DNA polymerase is heterotrimeric, consisting of a homodimer of accessory subunits plus a catalytic subunit. The protein encoded by this gene is the catalytic subunit of mitochondrial DNA polymerase. Defects in this gene are a cause of progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE).[6]

Structure

[edit]

POLG is located on the q arm of chromosome 15 in position 26.1 and has 23 exons. The POLG gene produces a 140 kDa protein composed of 1239 amino acids.[7][8] POLG, the protein encoded by this gene, is a member of the DNA polymerase type-A family. It is a mitochondrion nucleoid with an Mg2+ cofactor and 15 turns, 52 beta strands, and 39 alpha helixes.[9][10] POLG contains a polyglutamine tract near its N-terminus that may be polymorphic. Two transcript variants encoding the same protein have been found for this gene.[6]

Function

[edit]

POLG is a gene that codes for the catalytic subunit of the mitochondrial DNA polymerase, called DNA polymerase gamma.[6] The human POLG cDNA and gene were cloned and mapped to chromosome band 15q25.[11] In eukaryotic cells, the mitochondrial DNA is replicated by DNA polymerase gamma, a trimeric protein complex composed of a catalytic subunit, POLG, and a dimeric accessory subunit of 55 kDa encoded by the POLG2 gene.[12] The catalytic subunit contains three enzymatic activities, a DNA polymerase activity, a 3’-5’ exonuclease activity that proofreads misincorporated nucleotides, and a 5’-dRP lyase activity required for base excision repair. POLG activity is coordinated with mitochondrial SSB activity during DNA replication.[13]

Catalytic activity

[edit]

Deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1).[9][10]

Clinical significance

[edit]

Mutations in the POLG gene are associated with several mitochondrial diseases, progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE).[6] Pathogenic variants have also been linked with fatal congenital myopathy and gastrointestinal pseudo-obstruction and fatal infantile hepatic failure.[14][15] A list of all published mutations in the POLG coding region and their associated disease can be found at the Human DNA Polymerase Gamma Mutation Database.

Mice heterozygous for a Polg mutation are only able to replicate their mitochondrial DNA inaccurately, so that they sustain a 500-fold higher mutation burden than normal mice. These mice show no clear features of rapidly accelerated aging, indicating that mitochondrial mutations do not have a causal role in natural aging.[16]

Interactions

[edit]

POLG has been shown to have 50 binary protein-protein interactions including 32 co-complex interactions. POLG appears to interact with POLG2, Dlg4, Tp53, and Sod2.[17]

Notable people

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

POLG

View on Grokipedia
from Grokipedia
The POLG gene encodes the catalytic alpha subunit of gamma (pol γ), the sole responsible for the replication and repair of (mtDNA) in human cells. This complex is essential for maintaining mtDNA integrity, which is critical for and ATP production to meet cellular energy demands, particularly in high-energy tissues like the , muscle, and liver. Pathogenic variants in POLG disrupt pol γ function, often by impairing DNA synthesis, processivity, or binding, leading to mtDNA depletion, multiple deletions, or point mutations that compromise . These defects result in a continuum of POLG-related disorders, a group of mitochondrial diseases with overlapping phenotypes that vary by age of onset, inheritance pattern (autosomal recessive or dominant), and specific mutations. Early-onset forms, typically recessive and presenting before age 12, include severe conditions such as Alpers-Huttenlocher syndrome (AHS), characterized by refractory seizures, developmental regression, and , with an estimated prevalence of about 1 in 51,000. Juvenile and adult-onset phenotypes (ages 12–40 or later) often manifest as the ataxia neuropathy spectrum (ANS), myoclonic epilepsy myopathy sensory ataxia (MEMSA), or progressive external ophthalmoplegia (PEO), featuring progressive neuropathy, , epilepsy, and ophthalmoparesis, with better prognosis than infantile forms. Common POLG variants, such as c.2243G>C (p.Trp748Ser) and c.1399G>A (p.Ala467Thr), are recurrent across syndromes and severely impair activity, often reducing it to 1-30% of normal levels depending on the variant and combination. Diagnosis relies on clinical evaluation combined with molecular to identify biallelic or heterozygous pathogenic variants, while management is supportive, emphasizing avoidance of hepatotoxic agents like valproic acid, which can precipitate in affected individuals. Overall, POLG disorders highlight the critical role of mitochondrial genome maintenance in human health, with ongoing focusing on therapeutic strategies to mitigate mtDNA and improve energy metabolism. As of 2024, a phase 2 of deoxycytidine and deoxythymidine supplementation demonstrated safety and potential efficacy in alleviating symptoms of POLG-related disorders.

Gene Characteristics

Genomic Location and Organization

The POLG gene is situated on the long (q) arm of human chromosome 15 at cytogenetic band 15q26.1. In the GRCh38.p14 primary assembly, it occupies genomic coordinates 89,316,320 to 89,334,824 on the reverse (complementary) strand, spanning approximately 18.5 kb of genomic DNA. This locus encompasses the full gene structure, including regulatory elements upstream of the transcription start site. The gene is organized into 23 exons, with the first exon being non-coding and the mature coding sequence initiating in exon 2 and extending through exon 23. Exon lengths range from 53 to 768 bp, while introns adhere to the canonical GT-AG dinucleotide splice consensus at their boundaries. Relative to the RefSeqGene reference NG_008218.2 (total length 36,598 bp, including extended flanking sequences), representative exon positions include exon 1 at 5,001–5,123, exon 2 at 5,883–6,700, and exon 23 at 22,969–23,491, illustrating the interspersed distribution of coding and non-coding segments across the locus. Evolutionary conservation of POLG is pronounced among mammals, reflecting its essential role in mitochondrial maintenance. The sequences of the exons show 71–95% identity between and orthologs, with many exons identical in length. At the protein level, POLG shares about 85% sequence identity with mouse Polg, underscoring structural and functional similarity across . The core promoter region immediately upstream of the transcription start site is TATA-less and GC-rich (approximately 64% ), characteristic of genes involved in cellular . This region harbors a CpG island susceptible to , which modulates POLG expression in response to cellular stresses such as . Transcription factor binding sites within the promoter include consensus motifs for Sp1, a zinc-finger protein that coordinates nuclear with mitochondrial demands by integrating signals from metabolic pathways.

Transcript Variants and Expression

The POLG gene produces two main transcript variants according to , both encoding the same canonical of 1,239 . These variants differ only in their 5' untranslated regions (UTRs), with no impact on the coding sequence. Ensembl annotates 29 transcripts in total, including several predicted protein-coding isoforms of varying lengths, though many shorter ones (e.g., 51 ) are likely subject to and may not produce functional proteins. The canonical POLG features a polymorphic polyglutamine tract near its , encoded by a CAG trinucleotide repeat in 2, which varies in length from 4 to 13 repeats across individuals. This variation results in isoforms differing by up to 9 in the tract length, potentially influencing protein stability or function, though the tract is not generated by . No standard transcript variants involving specifically affecting this tract have been widely reported in healthy individuals. POLG expression is elevated in tissues with high energy demands, reflecting its role in mitochondrial DNA maintenance. According to GTEx data, median transcript per million (TPM) values are approximately 40–60 in , 20–40 in various regions (e.g., frontal cortex), and 50–70 in liver, underscoring tissue-specific regulation to support . The 3' UTR of POLG transcripts contains predicted binding sites for multiple microRNAs, which may contribute to of expression levels, as identified by bioinformatics tools like TargetScan.

Protein Structure

Primary and Domain Architecture

The POLG gene encodes the catalytic subunit of mitochondrial DNA polymerase gamma, consisting of 1,239 amino acids and exhibiting a molecular weight of approximately 140 kDa. Near the N-terminus, the protein features a polymorphic polyglutamine tract encoded by a CAG trinucleotide repeat in exon 2, with the most common allele comprising 10 repeats and a reported range of 5 to 16 repeats across human populations. This tract, located within the first 50 residues, contributes to the protein's overall sequence variability but does not directly participate in catalytic domains. The protein's domain architecture reflects its role as a family A , with distinct modular regions encoded by specific exons across its 23 exons. The 3'-5' domain, essential for mismatched , is primarily encoded by exons 2-7 and spans residues 64-424, incorporating three conserved motifs: Exo I (residues 196-200), Exo II (residues 267-275), and Exo III (residues 395-403). A central linker region (residues ~425-784) connects this to the C-terminal domain, encoded by exons ~15-23 (residues 785-1239), which houses the core synthetic machinery. Within the polymerase domain, an accessory 5'-deoxyribose phosphate (dRP) lyase subdomain facilitates by incising the phosphodiester backbone at apurinic/apyrimidinic sites, independent of divalent cations. The domain adopts a right-hand-like fold with three subdomains: the palm (containing catalytic motifs), fingers (for dNTP and template binding), and thumb (for duplex DNA grip). Sequence alignments with orthologs, such as those from T7 polymerase, reveal high conservation in these subdomains, particularly the palm's Pol A (residues 887-896), Pol B (943-958), and Pol C (1134-1141) motifs. Critical for , conserved residues at positions 890 and 1135 in the palm subdomain coordinate two Mg²⁺ ions at the , facilitating nucleotidyl transfer during . These residues, along with nearby acidic groups, ensure precise geometry for and fidelity in mitochondrial genome maintenance.

Quaternary Assembly and Modifications

The tertiary structure of the POLG protein, the catalytic subunit of mitochondrial DNA gamma, resembles the canonical "right-hand" architecture of family A DNA polymerases, featuring palm, fingers, and thumb subdomains within the polymerase domain, alongside an N-terminal 3'–5' domain for . These domains are connected by an extended spacer region of approximately 360 residues, which encompasses the accessory-interacting determinant (AID) subdomain (residues 511–570) and the intrinsic processivity (IP) subdomain (encompassing residues 475–510 and 571–785). This organization facilitates DNA binding, nucleotide selection, and catalytic activity. The of human POLG, determined at 3.24 resolution (PDB ID: 3IKM), highlights key structural elements such as the in the palm subdomain and the exonuclease cleft, providing insights into its during mtDNA replication. More recent structures, such as PDB 8UDL at 2.37 resolution (2024), offer higher-resolution views of the , including implications for mutations. Quaternary assembly of POLG occurs through formation of a heterotrimeric holoenzyme complex, consisting of one POLG catalytic subunit (approximately 140 kDa) bound to a homodimer of POLG2 accessory subunits (approximately 55 kDa each). This 1:2 enhances the enzyme's processivity on single-stranded DNA templates, enabling efficient replication of the mitochondrial genome by increasing nucleotide incorporation rates and stabilizing the polymerase-DNA interaction. The primary interface involves the AID subdomain of POLG engaging one POLG2 monomer via an extensive buried surface area of about 3500 Ų, while the second POLG2 monomer makes limited contacts, such as a between Arg232 of POLG and Glu394 of POLG2, contributing to the overall asymmetry and functional dynamics of the . Structural studies confirm that this assembly is essential for the high-fidelity synthesis required in mitochondria, distinguishing it from nuclear replicative polymerases. Post-translational modifications of POLG are critical for its mitochondrial localization, stability, and regulation. Upon synthesis, the N-terminal mitochondrial targeting signal (MTS, residues 1–35) is cleaved by the mitochondrial processing peptidase (MPP) in the matrix, generating the mature protein and ensuring proper import and function within mitochondria. This proteolytic processing is a conserved feature for nuclear-encoded mitochondrial proteins like POLG. at multiple serine and threonine residues has been predicted, potentially modulating enzymatic activity, though specific sites and kinases require further confirmation. Other modifications, such as PARylation, have been implicated in regulating POLG stability in response to DNA damage. These modifications collectively fine-tune POLG's role in mtDNA maintenance without altering its core catalytic properties.

Biological Function

Role in Mitochondrial DNA Replication

POLG encodes the catalytic subunit of DNA polymerase γ (Pol γ), the sole replicative DNA polymerase in human mitochondria responsible for synthesizing the mitochondrial genome. This 16.6 kb circular double-stranded DNA (mtDNA) is maintained through a specialized replisome that ensures processive replication despite the compact organelle environment. Pol γ integrates into this replisome by coordinating with TWINKLE helicase, which unwinds the DNA double helix at the replication fork, and mitochondrial single-stranded DNA-binding protein (mtSSB), which coats and stabilizes the resulting single-stranded DNA to prevent reannealing and secondary structure formation. This tripartite assembly—Pol γ holoenzyme, TWINKLE, and mtSSB—constitutes the minimal replisome capable of replicating the entire mtDNA molecule in vitro, achieving high processivity over long stretches without dissociation. The fidelity of Pol γ is critical for mtDNA integrity, as errors can accumulate rapidly due to the proximity of mtDNA to generated by . Pol γ achieves an error rate of approximately 1 in 10^6 for base substitutions, primarily through accurate nucleotide selection and 3'–5' activity that removes mismatched bases. This low helps prevent deleterious mtDNA mutations that could impair cellular energy production, contrasting with the higher error propensity in repetitive sequences where fidelity drops. mtDNA replication, driven by Pol γ, is regulated in coordination with cellular demands, showing upregulation during the of the in proliferating mammalian cells to match nuclear and support bioenergetic needs. In post-mitotic cells, replication persists continuously but at a basal rate to maintain mtDNA levels. This regulation contributes to steady-state mtDNA copy numbers of 1,000–10,000 per human cell, varying by tissue and metabolic state, ensuring adequate mitochondrial function without overload.

Enzymatic Activities and Kinetics

The catalytic subunit of γ (Pol γ), encoded by POLG, primarily exhibits 5'→3' activity, incorporating deoxynucleotide triphosphates (dNTPs) into the primer strand during synthesis. This activity follows the standard elongation mechanism: (DNA)n+dNTP→(DNA)n+1+PPi(\text{DNA})_n + \text{dNTP} \to (\text{DNA})_{n+1} + \text{PP}_i In the holoenzyme form, which includes the POLG-encoded catalytic subunit and accessory subunits, the Michaelis constant (K_m) for correct dNTP incorporation is approximately 0.8 μM for dATP opposite , with a (k_cat) of 45 s^{-1} under optimal conditions. These kinetic parameters reflect the enzyme's in nucleotide selection and extension, with similar K_m values (0.6–0.8 μM) observed for other correct base pairs like dGTP opposite and dTTP opposite . The activity is magnesium-dependent and sensitive to dNTP concentration, ensuring accurate replication of the mitochondrial genome. Pol γ also harbors intrinsic 3'→5' activity, functioning as a mechanism to excise mismatched from the 3' terminus of the growing DNA strand through . This activity is crucial for maintaining replication , removing errors at a rate of approximately 10–20 s^{-1} for mismatched bases, which is significantly faster than for correctly paired (<0.0001 s^{-1}). The exonuclease domain coordinates with the polymerase domain to partition the DNA substrate, enhancing overall error correction by 4- to 200-fold depending on the mismatch type. Pre-steady-state kinetic analyses reveal that this proofreading occurs without enzyme dissociation in many cases, allowing rapid correction during processive synthesis. In addition to its polymerase and exonuclease functions, Pol γ possesses 5'-deoxyribose phosphate (dRP) lyase activity, which participates in the base excision repair pathway by cleaving the dRP residue at 5' termini of incised apurinic/apyrimidinic sites. This cofactor-independent process proceeds via β-elimination, forming a Schiff base intermediate between the enzyme and the DNA substrate, as confirmed by sodium borohydride trapping experiments. The activity yields a k_cat of 0.26 min^{-1} (approximately 0.004 s^{-1}) and an apparent K_m of 0.6 μM, indicating it is catalytically slower than the lyase activity of nuclear polymerase β but sufficient for completing single-nucleotide gap repair in mitochondria.

Clinical and Pathological Significance

Associated Mitochondrial Disorders

Mutations in the POLG gene, which encodes the catalytic subunit of mitochondrial DNA polymerase gamma, are a leading cause of inherited mitochondrial disorders, accounting for a substantial proportion of cases of progressive external ophthalmoplegia and up to 2% of the population carrying pathogenic variants, particularly in Northern European descent. These disorders exhibit a broad clinical spectrum influenced by inheritance patterns, with autosomal recessive forms typically presenting in childhood or early adulthood and autosomal dominant forms often manifesting later in life. The overall prevalence of POLG-related disorders is estimated at around 1 in 10,000 to 1 in 50,000 individuals, though specific syndromes like Alpers-Huttenlocher syndrome have a reported frequency of about 1 in 51,000. Key syndromes include progressive external ophthalmoplegia type 1 (PEOA1), Alpers-Huttenlocher syndrome, and sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO). PEOA1, which can be autosomal dominant or recessive, is characterized by progressive weakness of the extraocular muscles leading to ptosis and ophthalmoparesis, often accompanied by skeletal myopathy, exercise intolerance, and sometimes parkinsonism or peripheral neuropathy in later stages. Alpers-Huttenlocher syndrome, an autosomal recessive disorder with onset typically before age 2 years, features severe hepatocerebral involvement, including intractable epilepsy, developmental regression, hypotonia, and acute liver failure often triggered by valproate exposure. SANDO, also autosomal recessive, presents in adulthood with sensory ataxia, dysarthria, ophthalmoparesis, and peripheral neuropathy, progressing to include hearing loss and psychiatric symptoms. Diagnosis of POLG-related disorders relies on a combination of clinical evaluation, genetic testing confirming biallelic (recessive) or heterozygous (dominant) pathogenic variants in POLG, and supportive histopathological findings. Muscle biopsies frequently reveal ragged-red fibers indicative of mitochondrial proliferation and cytochrome c oxidase (COX)-negative fibers, reflecting impaired oxidative phosphorylation. Affected tissues, such as liver or muscle, often show mtDNA depletion with reductions exceeding 70% compared to controls, particularly in recessive childhood-onset syndromes like Alpers-Huttenlocher, underscoring the role of polymerase dysfunction in mtDNA maintenance. Common mutation hotspots in POLG, such as those in the polymerase domain, are frequently implicated across these phenotypes.

Mutation Types and Pathogenic Mechanisms

The POLG gene harbors over 300 pathogenic variants identified to date, encompassing missense, nonsense, frameshift, splice site, and large deletion/duplication mutations that disrupt the function of the DNA gamma catalytic subunit. These variants are distributed throughout the gene, with a notable concentration in the domain and linker region; prominent examples include the recurrent missense mutation p.Ala467Thr (c.1399G>A) in exon 7, which is found in approximately 0.6% of certain populations and compromises catalytic efficiency, as well as compound cis variants like p.[Thr251Ile;Pro587Leu] prevalent in Italian cohorts at about 1%. Other frequently reported mutations, such as p.Trp748Ser (c.2243G>C) and p.Gly848Ser (c.2542G>A), cluster in the and exhibit population-specific founder effects, particularly in Finnish and European groups. Pathogenic mechanisms primarily involve loss-of-function effects that impair (mtDNA) maintenance, leading to depletion or multiple deletions. Missense mutations often reduce activity by 20-80% relative to wild-type, while more severe ones such as p.Ala467Thr diminish activity to as low as 4% through decreased catalytic rate (k_cat) and impaired substrate binding. In the heterotrimeric holoenzyme complex (one POLG subunit with two accessory POLG2 subunits), certain dominant mutations exert dominant-negative interference by forming dysfunctional heterodimers or heterotrimers that hinder overall processivity and mtDNA synthesis rates. Additionally, some variants disrupt the 3'→5' domain, increasing error rates during replication and promoting somatic mtDNA point mutations or deletions, as demonstrated in models with impaired activity like the D198A substitution. Emerging therapeutic strategies, including supplementation with deoxycytidine and deoxythymidine and small molecules that restore mutant POLG function, show promise in preclinical and early clinical trials as of 2025. Genotype-phenotype correlations reveal that biallelic null or severe loss-of-function mutations, such as nonsense or frameshift variants leading to absent protein, typically cause early-onset infantile syndromes like Alpers-Huttenlocher syndrome with rapid neurological decline. In contrast, heterozygous missense mutations, often acting dominantly, are associated with adult-onset progressive external ophthalmoplegia (PEO) or ataxia-neuropathy spectrum disorders, where residual activity (e.g., 5-30% in compound variants) allows later manifestation. These patterns underscore how allele dosage and biochemical severity modulate disease onset and progression.

Molecular Interactions

Protein-Protein Binding Partners

The DNA polymerase gamma (POLG) catalytic subunit forms a core heterotrimeric holoenzyme through tight physical binding to the accessory subunit encoded by POLG2, with a dissociation constant (Kd) of approximately 9 nM for the wild-type complex. This high-affinity interaction primarily involves interfaces between the accessory domain of POLG and specific DNA-binding regions (DBRs) in POLG2, which stabilizes the enzyme on DNA templates and enhances overall replication fidelity. POLG functionally cooperates with TWINKLE (TWNK), the mitochondrial replicative , as part of the to support mtDNA replication, where TWINKLE unwinds the DNA duplex ahead of . The mitochondrial single-stranded (mtSSB, or SSBP1) engages in direct physical contact with POLG, stimulating its activity approximately 8-fold through that coats and protects single-stranded DNA intermediates during replication. This interaction balances attractive and repulsive forces to optimize polymerase displacement along the template. TFAM modulates mtDNA to promote access to replication origins, facilitating efficient of lagging-strand synthesis by POLG. POLG also interacts with the mitochondrial protease LonP1, which binds to a specific region of POLG to coordinate DNA and mitochondrial . Experimental validation of these and additional interactions has been achieved through two-hybrid screening and co-immunoprecipitation assays, with databases such as integrating data to identify over 50 interactors for POLG, including high-confidence physical associations supported by co-purification and genetic evidence.

Functional and Regulatory Networks

POLG integrates into regulatory networks that respond to cellular energy status and DNA integrity signals. During energy stress, such as elevated AMP/ATP ratios, activation of (AMPK) enhances POLG-mediated (mtDNA) maintenance, alleviating phenotypes associated with mtDNA depletion by promoting catabolic shifts that support replication fidelity. In parallel, POLG engages in a feedback loop with , where accumulated mtDNA damage triggers p53 translocation to mitochondria, interacting with POLG to modulate repair; unresolved damage then promotes p53-dependent to prevent propagation of defective mtDNA. In pathway integration, POLG contributes to mitochondrial base excision repair (BER) by filling gaps after incision of oxidative lesions. Specifically, 8-oxoguanine DNA glycosylase (OGG1) excises damaged bases like 8-oxoG, generating abasic sites processed by apurinic/apyrimidinic endonuclease (APE1), with POLG then performing the resynthesis step in coordination with these enzymes to restore mtDNA integrity under oxidative conditions. Additionally, POLG interacts with superoxide dismutase 2 (SOD2) in the oxidative stress response, where SOD2 reduces superoxide radicals to limit mtDNA damage, thereby modulating POLG's replicative burden and preventing error-prone synthesis. Evolutionarily, POLG exhibits high conservation across metazoans, reflecting its essential role in mtDNA replication from to vertebrates, with the catalytic subunit maintaining core structural motifs for and activities. In humans, the N-terminal polyglutamine tract of POLG shows species-specific expansions and polymorphism (typically 6-14 glutamines), potentially enabling finer regulatory tuning through altered protein interactions or stability compared to more uniform tracts in other metazoans.

References

  1. https://medlineplus.gov/genetics/gene/polg/
  2. https://www.sciencedirect.com/science/article/pii/S0005272808007044
  3. https://www.ncbi.nlm.nih.gov/books/NBK26471/
  4. https://www.nature.com/articles/gim201735
  5. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00319-5/fulltext
  6. https://www.ncbi.nlm.nih.gov/gene/5428
  7. https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000140521
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC2905783/
  9. https://gtexportal.org/home/gene/POLG
  10. https://www.genecards.org/cgi-bin/carddisp.pl?gene=POLG
  11. https://www.sciencedirect.com/science/article/abs/pii/S1567724914000130
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2742478/
  13. https://www.uniprot.org/uniprotkb/P54098/entry
  14. https://www.sciencedirect.com/science/article/pii/S0092867409010447
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8796686/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3018533/
  17. https://www.rcsb.org/structure/3IKM
  18. https://www.rcsb.org/structure/8UDL
  19. https://www.ahajournals.org/doi/10.1161/ATVBAHA.124.321682
  20. https://www.embopress.org/doi/10.1038/sj.emboj.7600257
  21. https://academic.oup.com/hmg/article/15/suppl_2/R244/626889
  22. https://www.nature.com/articles/s41598-017-10843-8
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC8533111/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC3381518/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC2846211/
  26. https://www.pnas.org/doi/10.1073/pnas.95.21.12244
  27. https://doi.org/10.1038/s41582-018-0101-0
  28. https://umdf.org/polg/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9289853/
  30. https://pubmed.ncbi.nlm.nih.gov/16024923/
  31. https://www.jbc.org/article/S0021-9258%2820%2941392-4/fulltext
  32. https://academic.oup.com/nar/article/39/21/9072/1096227
  33. https://www.nature.com/articles/s41586-025-08856-9
  34. https://doi.org/10.1093/nar/gkad679
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC8440931/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8488568/
  37. https://academic.oup.com/nar/article/52/13/7863/7699954
  38. https://string-db.org/network/9606.ENSP00000399851
  39. https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.70006
  40. https://www.embopress.org/doi/10.1038/sj.emboj.7600819
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC4546830/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4419789/
  43. https://www.sciencedirect.com/science/article/abs/pii/S0304394010004581
Add your contribution
Related Hubs
User Avatar
No comments yet.